-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivatives更多Trade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo Clearing更多Euronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in Europe更多Euronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)更多The new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indices更多The first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Kiadis Pharma
02/07/2015
Kiadis Pharma celebrates IPO by sounding gong
By sounding the gong, Kiadis Pharma celebrates its IPO on Euronext Amsterdam and Euronext Brussels. CEO of Kiadis Pharma, Manfred Rüdiger, sounds the gong to open trading.
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders.
Rüdiger: “We are delighted to have joined Euronext today. Kiadis Pharma's IPO received significant interest from local, European and US investors and now we intend to advance our pipeline of products that will potentially save the lives of thousands of blood cancer and inherited blood disorder patients.”
For more information: www.kiadis.com